Open archive
Clear filters
Showing 73-83 of 83 published briefings.
Sector archive
Published briefings for one sector.
Browse recent results from companies in the same sector.
Green Cross Health (GXH)HY23Released 25 November 2022
PBT up 20.3% as Medical and Community offset pharmacy weakness
The dominant pharmacy segment lost revenue share and earnings while a 30.3% effective tax rate clipped NPAT growth to 17.5%.
Published 22 April 2026
Read briefingRyman Healthcare (RYM)HY23Released 18 November 2022
NZ$281m working-capital build cut pre-lease FCF to NZ$51.8m as NPAT fell 31%
Underlying profit rose 44.8% but reported NPAT fell 31.1% as receivables expanded and capex jumped 56%, draining cash flow despite revenue growth.
Published 28 April 2026
Read briefingBlis Technologies (BLT)HY23Released 10 November 2022
Cash inflow leaned on NZ$1.1m working-capital release as loss narrowed only 6.1%
Revenue grew 10.2% under the strategy reset, but operating cash was flattered by debtor and inventory releases that broke the historical build
Published 22 April 2026
Read briefingOceania Healthcare (OCA)HY23Released 7 November 2022
PBT fell 74.3% on lower Village revaluations as cash conversion slid
Realised sales gains rose 12%, but cash conversion dropped to 81.2% and the 1.9c dividend exceeds NPAT cover.
Published 22 April 2026
Read briefingRua Bioscience (RUA)FY22Released 29 August 2022
Cash falls to $1.9m as operating burn widens to $6.8m
First product sales arrived but losses widened materially, leaving only months of cash at the current operating burn rate.
Published 22 April 2026
Read briefingPromisia Healthcare (PHL)FY22Released 30 June 2022
First full year of acquired aged-care lifts revenue to $19.0m
Headline +213.6% growth reflects the December 2020 acquisition lapping into a full period, not underlying expansion of the existing footprint.
Published 29 April 2026
Read briefingRyman Healthcare (RYM)FY22Released 17 June 2022
Reported NPAT jumped 63.8% but underlying profit grew only 13.6%
Investment property revaluations drove the headline gain while capex at 55.9% of revenue absorbed most of the operating cash flow expansion.
Published 29 April 2026
Read briefingTruScreen Group (TRU)FY22Released 30 May 2022
Revenue grew 48% but FY22 loss widened to $7.9m as cash fell to $2.8m
Operating leverage moved the wrong way in the second half, with the implied H2 loss running roughly five times H1 and cash burn consuming nearly half
Published 23 April 2026
Read briefingThird Age Health Services (TAH)FY22Released 30 May 2022
Cash conversion fell to 90% as acquisitions drove 7.5% revenue growth
Gross margin expanded 300bps to 63% on the GP portfolio shift, but operating cash flow weakened and ROE eased from 73.4% to 50.2%.
Published 22 April 2026
Read briefingRua Bioscience (RUA)HY22Released 25 February 2022
Operating cash burn nearly doubled to $3.7m before first revenue
Headline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.
Published 22 April 2026
Read briefingTruscreen Group (TRU)HY22Released 29 November 2021
Operating cash burn widened to NZ$1.7m as cash fell to NZ$3.7m
Reported loss narrowed in dollar terms but operating cash outflow grew, drawing cash down 17.8% and total equity 13.4% over the period.
Published 23 April 2026
Read briefingGet reporting-season briefings
Get full NZX result briefings by email as new coverage is published.